Urothelial Carcinoma Treatment Market Size, Competitive Landscape and Forecast to 2023

Market Highlights:

Urothelial carcinoma is also known as transition cell carcinoma. It is a type of cancer that occurs mostly in the urinary system and is one of common bladder cancer of ureter and urethra. Due to the increasing prevalence of bladder cancer urothelial carcinoma treatment market is growing. Increasing funding for research and development activities to develop new cancer therapies is also one the factor responsible for the growth of this market. More initiation has been taken by government and non-government organizations regarding awareness for early diagnosis of cancer, as a result, these factors are expected to boost the Urothelial Carcinoma Treatment Market Growth during the forecast period.

Key Players:

GlaxoSmithKline plc, Genentech, Inc., Novartis AG, Dendreon, Merck KGaA, Eisai Co., Sanofi S.A., and Bristol-Myers Squibb.

Segmentation:

  • The global urothelial carcinoma treatment market has been segmented on the basis of types, treatment, and end-users.
  • Based on type the global urothelial carcinoma treatment is segmented into non-invasive and invasive urothelial carcinoma treatment.
  • On the basis of treatment, the market is segmented into immunotherapy, radiotherapy, and chemotherapy.
  • Based on end-user the urothelial carcinoma market is segmented into hospital pharmacy, retail pharmacy, and others.

 

Regional Analysis:

On a regional basis, the market is segmented into Americas, Europe, Asia-Pacific, Middle East, and Africa.

Americas is likely to dominate the urothelial carcinoma treatment market owing to the increasing prevalence of bladder cancer, increasing investment in research and development of new bladder cancer treatment. According to the American cancer society report, about 79030 cases of bladder cancer was reported in 2017 in the US.

Europe is the second largest market for the urothelial carcinoma treatment followed by Asia-Pacific. Due to growing awareness regarding early diagnosis of bladder cancer and developed healthcare infrastructure with increasing prevalence of urothelial cancer. Asia Pacific shows the fastest growth in the market due to the low cost of R&D. India and China are expected to be the fastest growing market for bladder cancer treatment.

The Middle East and Africa has the lowest market for urothelial carcinoma treatment due to poor medical facilities and lack of technology.